Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/ dexamethasone in patients with newly diagnosed multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 7, Issue SUPPL. 4, 2007, Pages

  Porter, Christopher A ^a   Rifkin, Robert M ^b  

^a HealthOne   (United States)

^b Rocky Mountain Blood and Marrow Transplant Program   (United States)

Author keywords

Chemotherapy; Health care resource utilization; Outcome; Survival

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34249791805     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.s.016     Document Type: Article

References (18)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336:1657-1664.
2. DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles & Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
3. Hussein MA. Modifications to therapy for multiple myeloma: pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist 2003; 8(suppl 3):39-45.
4. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33:86-89.
5. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 2:882-885.
6. Durie BG, Jacobson J, Barlogie B, et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol 2004; 22:1857-1863.
7. Lokhorst HM, Meuwissen OJ, Bast EJ, et al. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989; 71:25-30.
8. Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9:711-716.
9. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-436.
10. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-19.
11. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing sutface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36:55-63.
12. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line trearmenr of metastatic breast cancer. Ann Oncol 2004; 15:440-449.
13. 2. Ann Oncol 2000; 11:1029-1033.
14. Hussein MA, Wood L, Hsi E, et al. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002; 95:2160-2168.
15. Alexanian R, Balcerzak S, Bonnet JD, et al. Prognostic factors in multiple myeloma. Cancer 1975; 36:1192-1201.
16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
17. Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compated with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 2006; 106:848-858.
18. Dimopoulos MA, Pouli A, Zervas K, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003; 14:1039-1044.